Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro - PubMed (original) (raw)
Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro
B J Sugarman et al. Science. 1985.
Abstract
Modulation of the growth of human and murine cell lines in vitro by recombinant human tumor necrosis factor-alpha (rTNF-alpha) and recombinant human interferon-gamma (rIFN-gamma) was investigated. rTNF-alpha had cytostatic or cytolytic effects on only some tumor cell lines. When administered together with rIFN-gamma, rTNF-alpha showed enhanced antiproliferative effects on a subset of the cell lines tested. In contrast to its effects on sensitive tumor cells, rTNF-alpha augmented the growth of normal diploid fibroblasts. Variations in the proliferative response induced by rTNF-alpha were apparently not due to differences in either the number of binding sites per cell or their affinity for rTNF-alpha. These observations indicate that the effects of rTNF-alpha on cell growth are not limited to tumor cells, but rather that this protein may have a broad spectrum of activities in vivo.
Similar articles
- Diversity of the effect of recombinant tumor necrosis factors alpha and beta on human myelogenous leukemia cell lines.
Beran M, Andersson BS, Kelleher P, Whalen K, McCredie K, Gutterman J. Beran M, et al. Blood. 1987 Mar;69(3):721-6. Blood. 1987. PMID: 3028534 - Cytostatic and cytotoxic activity of tumor necrosis factor on human cancer cells.
Ruggiero V, Latham K, Baglioni C. Ruggiero V, et al. J Immunol. 1987 Apr 15;138(8):2711-7. J Immunol. 1987. PMID: 3031163 - Induction of the synthesis of tumor necrosis factor receptors by interferon-gamma.
Ruggiero V, Tavernier J, Fiers W, Baglioni C. Ruggiero V, et al. J Immunol. 1986 Apr 1;136(7):2445-50. J Immunol. 1986. PMID: 3005411 - Recombinant human TNF-alpha: preclinical studies and results from early clinical trials.
Saks S, Rosenblum M. Saks S, et al. Immunol Ser. 1992;56:567-87. Immunol Ser. 1992. PMID: 1550875 Review.
Cited by
- Non-small cell lung cancer sensitisation to platinum chemotherapy via new thiazole-triazole hybrids acting as dual T-type CCB/MMP-9 inhibitors.
Gamal H, Ismail KA, Omar AME, Teleb M, Abu-Serie MM, Huang S, Abdelsattar AS, Zamponi GW, Fahmy H. Gamal H, et al. J Enzyme Inhib Med Chem. 2024 Dec;39(1):2388209. doi: 10.1080/14756366.2024.2388209. Epub 2024 Aug 14. J Enzyme Inhib Med Chem. 2024. PMID: 39140776 Free PMC article. - Chimeric antigen receptor dendritic cells targeted delivery of a single tumoricidal factor for cancer immunotherapy.
Duan R, Milton P, Sittplangkoon C, Liu X, Sui Z, Boyce BF, Yao Z. Duan R, et al. Cancer Immunol Immunother. 2024 Aug 6;73(10):203. doi: 10.1007/s00262-024-03788-1. Cancer Immunol Immunother. 2024. PMID: 39105847 Free PMC article. - Highlighting fibroblast plasticity in lung fibrosis: the WI-38 cell line as a model for investigating the myofibroblast and lipofibroblast switch.
Vásquez-Pacheco E, Marega M, Lingampally A, Fassy J, Truchi M, Goth K, Trygub L, Taghizadeh S, Bartkuhn M, Alexopoulos I, Dong Y, Lebrigand K, Gunther A, Chen C, Zhang J, Chao CM, Al Alam D, El Agha E, Mari B, Bellusci S, Rivetti S. Vásquez-Pacheco E, et al. Theranostics. 2024 Jun 11;14(9):3603-3622. doi: 10.7150/thno.93519. eCollection 2024. Theranostics. 2024. PMID: 38948058 Free PMC article. - Continuous TNF-α exposure in mammary epithelial cells promotes cancer phenotype acquisition via EGFR/TNFR2 activation.
Lee JH, Hallis SP, Kwak MK. Lee JH, et al. Arch Pharm Res. 2024 May;47(5):465-480. doi: 10.1007/s12272-024-01497-y. Epub 2024 May 11. Arch Pharm Res. 2024. PMID: 38734854 - Trastuzumab: dreams, desperation and hope.
Shepard HM. Shepard HM. Nat Rev Cancer. 2024 May;24(5):287-288. doi: 10.1038/s41568-024-00676-9. Nat Rev Cancer. 2024. PMID: 38491271 No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources